Naslov
Comorbidity as a risk factor for the development of severe COVID-19 disease caused by Delta and Omicron variant

Autori
Vuković, Vlasta ; Viljevac, Jelena ; Likić, Robert ; Popović, Filip ; Budimir, Bernard ; Vukić Dugac, Andrea ; Baričević, Denis ; Pevec, Branko ; Samaržija, Miroslav ; Pavliša, Gordana

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, neobjavljeni rad, znanstveni

Skup
Kongres Hrvatskog torakalnog društva TORAKS 2022

Mjesto i datum
Zagreb, Hrvatska, 24.09.2020. - 25.09.2020

Vrsta sudjelovanja
Poster

Vrsta recenzije
Domaća recenzija

Ključne riječi
COVID 19, comorbidity

Sažetak
In January 2022, the B.1.1.529 (Omicron) variant of SARS-CoV-2 suppressed the B.1.617.2 (Delta) variant in Croatia. Epidemiological studies have shown that Omicron variant infection has a significantly lower risk of hospitalizations compared to the Delta variant. The aim of our study was to describe the characteristics of patients hospitalized during the Delta and Omicron dominance periods and to analyse the difference in comorbidities. Data obtained from the hospital electronic database were retrospectively analyzed. The study included 100 patients with PCR- proven SARS-CoV-2 infection. We included 50 patients hospitalized in the COVID-19 ward in November 2021 (Delta predominant period) and 50 patients from February 2022 (Omicron). Results: The group of patients treated in November 2021 consisted of 29 men and 21 women, the median ± SD age was 73 ± 17.04 years. 40% were vaccinated (n = 20/50). 68% had arterial hypertension (n = 34/50), 28% had diabetes (n = 14/50), 16% dyslipidemia (n = 8/50), 56% had chronic heart disease (n = 28/50), 36% had chronic renal failure (n = 18/50), 48% a liver lesion (n = 24/50), 12% had a stroke (n = 6/50). The median ± SD of the total number of comorbidities was 5 ± 2.8. Patients treated in February 2022 were 22 men and 28 women, the median ± SD age was 76 + 14.69 years. 48% were vaccinated (n = 24/50). 60% had arterial hypertension (n = 30/50), 54% had diabetes (n = 12/50), 20% dyslipidemia (n = 10/50), 50% had chronic heart disease (n = 28/50), 20% had chronic renal failure (n = 10/50), 34% a liver lesion (n = 17/50), 18% had a stroke (n = 9/50). The median ± SD of the total number of comorbidities was 5 ± 2.76. The number of cardiac comorbidities was statistically significantly higher in the group of patients treated during the dominance of the Delta strain of SARS-Co-2 virus (p = 0.046). Conclusion: The group of COVID-19 patients treated during the dominance of Delta and Omicron variants of SARS-Co-2 virus differed significantly in the number of cardiac comorbidities. No statistically significant difference was found among other comorbidities.

Izvorni jezik
Engleski

POVEZANOST RADA